Piedmont Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Piedmont Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13,145	Closed	-$461K	–	1234
2019 Q1	$461K	Buy	13,145 +768	+6%	+$28.6K	0.02%	570
2018 Q4	$411K	Buy	12,377 +409	+3%	+$17.6K	0.02%	540
2018 Q3	$603K	Sell	11,968 -20,184	-63%	-$997K	0.03%	443
2018 Q2	$1.92M	Buy	32,152 +21,137	+192%	+$1.09M	0.09%	225
2018 Q1	$504K	Buy	11,015 +479	+5%	+$20K	0.01%	413
2017 Q4	$420K	Sell	10,536 -508	-5%	-$20.1K	0.01%	464
2017 Q3	$442K	Buy	11,044 +172	+2%	+$7.44K	0.01%	460
2017 Q2	$469K	Buy	+10,872	New	+$387K	0.01%	434

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Piedmont Investment Advisors's SUPN Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 13,145 shares — an estimated $461K sold.

Piedmont Investment Advisors first reported a position in SUPN in Q2 2017 and held it in 8 quarters. The position peaked at $1.92M in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Piedmont Investment Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Piedmont Investment Advisors sold 13,145 Supernus Pharmaceuticals shares in Q2 2019, an estimated $461K.
Piedmont Investment Advisors first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 8 quarters.
Piedmont Investment Advisors's Supernus Pharmaceuticals position peaked at $1.92M in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.